Vanda Pharmaceuticals’ Earnings Call: FDA Outcome Certainty vs. No Speculation, NEREUS Launch Timeline Shifts

<<>>

Date of Call: Aug 5, 2026

Financials Results

• Revenue: Total revenues for Q2 2026 were $50.5M, a 4% decrease compared to $52.6M in Q2 2025 and a 2% decrease sequentially from $51.7M in Q1 2026.

Guidance:

• Total revenue for 2026 expected to be between $240 and $290 million, implying ~23% growth at midpoint vs. 2025.
• FNAPT and Basanti net product sales expected to be between $150 and $170 million, implying ~36% combined growth at midpoint vs. 2025 FNAPT revenue.
• Other net product sales (Hetlios, Pomvori, Nereus) expected to be between $80 and $90 million.
• Nereus net product sales expected to be between $10 and $30 million.
• Operating expenses expected to begin moderating later in 2026 and more significantly in 2027.
• Cash burn in 2026 likely to be greater than in 2025, but company expects sufficient resources to fund operations through at least end of 2027.

Business Commentary:

Revenue Performance and Product Sales:

• Vanda Pharmaceuticals reported total revenues of $102.2 million for the first six months of 2026, flat compared to $102.6 million in the same period in 2025.
• FNAPT net product sales increased by 24% to $65.5 million for the first six months of 2026, driven by increased volume.
• The flat total revenue was due to a decrease in Hetlios revenue from generic competition and timing of shipments.

Growth in Specific Products:

• FNAPT total prescriptions (TRX) increased by 31% compared to the second quarter of 2025.
• FNAPT new patient starts (NBRX) increased by 32% compared to the second quarter of 2025.
• This growth was driven by continued commercialization efforts for FNAPT in bipolar I disorder.

Challenges with Hetlios:

• Hetlios net product sales decreased by 42% to $21.5 million for the first six months of 2026.
• The decrease was due to a reduction in volume from continued generic competition and timing of shipments.
• Despite the competition, Hetlios maintained market share leadership.

Launch of New Products:

• Nereus net product sales were $1 million for the first six months of 2026, launched in May 2026.
• Initial inventory stocking by wholesalers amounted to $15.2 million, with constrained revenue of $12.6 million.
• Sales are expected to grow with personal promotion by the existing sales force later in 2026.

Operating Expenses and Cash Position:

• Operating expenses for the first six months of 2026 increased by $34.1 million to $216.3 million, driven by higher SG&A and R&D expenses.
• The cash position decreased by $93.8 million from December 31, 2025, due to net losses and a one-time milestone payment.
• The company expects operating expenses to moderate later in 2026 and more significantly in 2027.

Sentiment Analysis:

Overall Tone: Positive

• "We're pleased with the continuous strong growth of FNAPT and the enthusiastic response to Nereus... we believe Vanda is well-positioned for meaningful commercial expansion and pipeline value creation." "FNAPT total prescriptions... up 31% compared to the second quarter of 2025." "FNAPT new patient starts... up 32% compared to the second quarter of 2025." "We believe that our current resources... provide a solid foundation to advance our objectives."

Q&A:

• Question from Jan (Jefferies): With respect to the Nereus launch experience, where are you seeing the biggest drop-off in the patient funnel? What metrics should investors watch to judge whether Nereus falls at the low or high end of the $10 to $30 million revenue range?
  Response: Very early in launch; metrics to watch include sales force doctor visits, market receptivity, patient acquisition, refill rates, and pills per fill.

• Question from Jan (Jefferies): Following the July 20th pre-hearing conference and August 3 evidentiary disclosure deadline, what became clear about the Hetlios hearing? Which issue is most likely to drive the outcome?
  Response: The pre-hearing was a process call; no speculation on litigation strategy, but confident in presenting the case, awaiting a favorable recommendation early in 2027.

• Question from Madison (Firm not specified): What exactly does personal promotion for Nereus start? How many reps? Does that fit within the OPEX moderation guidance? What drove the Q2 R&D expense?
  Response: Will use existing ~300 FNAPT and ~50 Pomvori reps for detailing; OPEX moderation driven by conclusion of Phase III programs and commercial supply prep; Q2 R&D increase due to ramp-up of those programs and pre-approval inventory expenses for IMSA Dolomab.

• Question from Andrew Tsai (Jefferies): On the VQW765 program, what gives confidence in Phase 3 success and why could efficacy look better?
  Response: Phase III design is similar to the positive Phase II study with the same primary endpoint; appropriately powered based on Phase II learnings.

• Question from Andrew Tsai (Jefferies): What is the filing strategy/timing for Nereus in GLP-1 induced vomiting? Have you aligned with the FDA on Phase 3 design? What are you hoping to see relative to Phase 2?
  Response: A supplemental NDA filing is anticipated following a similar Phase III study design; positive Phase II showed 60% placebo vs 30% Nereus vomiting; ongoing FDA discussions on statistical analysis plan.

Contradiction Point 1

FDA Hearing Process and Outcome Certainty

Contradiction on the nature of the pre-hearing step and the company's stated confidence level.

How will Yonzi's substitution for Ram impact the company's earnings strategy? - Yonzi (sitting in for Ram)

2026Q2: The pre-hearing was a procedural step, not a review of facts. The company is confident in its ability to present its case to the Administrative Law Judge. The process will continue throughout the year, with a favorable recommendation expected early in 2027. - Daniel McGuire(General Counsel)

What became clear about the FDA hearing for Hetlios following the July 20 pre-hearing conference and August 3 evidentiary disclosure deadline, and which issue (e.g., interpretation of statutes, endpoint validity) is most likely to drive the outcome? - Jan Z (H.C. Wainwright)

2026Q2: The pre-hearing was a procedural call, not a substantive review of facts. The company is confident in its case presentation to the Administrative Law Judge and hopes for a favorable recommendation early in 2027. No speculation is made on the outcome. - Dr. Mihalis Polymeropoulos(CEO) and Daniel McGuire(General Counsel)

Contradiction Point 2

NEREUS Launch Sales Cadence and Promotional Timing

Contradiction on when revenue growth begins and promotional activities start.

Yonzi (sitting in for Ram) - Yonzi (sitting in for Ram)

2026Q2: [Personal promotion using the existing sales force will begin later in 2026. Key metrics for investors to watch include: doctor engagement and product receptivity, patient acquisition metrics, refill rates, and pills per fill. These will help predict the revenue trajectory.] - Kevin Moran(CFO)

What are the biggest drop-off points in the Nereus patient funnel, and which metrics should investors monitor to assess whether revenue will fall at the low or high end of the $10–$30M range? - Faye (Jefferies) – On behalf of Andrew Tsai

2026Q1: [Revenue is expected to grow progressively through 2026 as promotional activities (DTC campaign) increase. The launch timing (mid-Q2) supports a ramp-up in sales.] - Kevin Moran and Dr. Mihael Polymeropoulos(CEO)

Contradiction Point 3

Commercial Launch Timing for Imsidolimab (GPP)

Contradiction on the expected timing for the GPP launch relative to FDA decision.

Andrew Tsai (Jefferies) - Andrew Tsai (Jefferies)

2026Q2: [The launch is very early (started May 2026 with DTC and web portal). Personal promotion using the existing sales force will begin later in 2026.] - Kevin Moran(CFO)

What is the filing strategy and timing for the GLP-1 induced vomiting indication for Nereus, have you aligned with the FDA on Phase III trial design, and what are your latest thoughts on the Phase II findings? - Madison El-Saadi (B. Riley)

2026Q1: [The FDA submission supports both acute treatment (1 injection) and maintenance (every 4 weeks). A commercial launch is expected within the first half of 2027, not immediately after the PDUFA date (Dec 12, 2026)... - Dr. Mihael Polymeropoulos(CEO)

Contradiction Point 4

Nereus Launch Timing and Commercial Readiness

Contradiction on when commercial launch materials will be ready and launch begins.

Yonzi (sitting in for Ram) - Yonzi (sitting in for Ram)

2026Q2: The launch is very early (started May 2026) with DTC and web portal. - Kevin Moran(CFO)

What metrics should investors monitor to evaluate the patient funnel drop-offs and determine Nereus' revenue outcome within the $10–$30M range? - Unknown Analyst (Analyst)

20260212-2025 Q4: Commercial materials are being prepared and are expected to be ready by late Q2 or early Q3 2026, enabling launch readiness. - Mihael Polymeropoulos(CEO)

Contradiction Point 5

Iloperidone GTN (Vasanti) Launch Timing and Revenue Impact

Contradiction on the launch timing and its financial impact on Fanapt in 2026.

What were Madison's earnings for the quarter? - Madison

2026Q2: Personal promotion for Nereus will begin later in 2026... resources are sufficient to reach prescribers. - Kevin Moran(CFO)

When does the Nereus personal promotion start, how many reps are involved, and does it align with guided expense moderation? - Madison Wynne El-Saadi (B. Riley Securities)

20260212-2025 Q4: Commercial launch is expected in Q3 2026 once commercial supplies are ready. - Mihael Polymeropoulos(CEO)

<<>>